Joaquin Rodrigo, General Manager – Sandoz Iberia
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
Sandoz was a company that merged with Ciba-Geigy to form Novartis. The name was later reused as the name of Novartis’ generic drug subsidiary.
The general manager for Sandoz Iberia, Joaquin Rodrigo, comments on the intricacies of the Spanish healthcare system, the main trends driving generics and biosimilars in the country and shares his…
Sandoz Switzerland’s Jan Tangermann highlights the importance of the Swiss affiliate to the global group and how it was able to provide sustainable and reliable access to critical and essential…
Carol Lynch of Sandoz US talks candidly on the US generics market from an international perspective, market access, biosimilars uptake, talent attraction, and navigating the COVID-19 crisis. The US…
Sandoz’s Jiří Hanzlík, country head for the Czech Republic, evaluates the Czech affiliate’s role in contributing to the success of Sandoz globally as well as its position in the country.…
Fabio Sperandei has been the country head for Sandoz Malaysia for four years. Here, he explains the key success factors that led Sandoz to become the leading multinational generic company…
Dr. Altan Demirdere, president of Novartis Group in Turkey discusses the long history of Novartis and Sandoz in the country, as well as the current issues between the Turkish pharmaceutical…
Mourad Ishak, country president Novartis and general manager Sandoz Algeria reveals Novartis’ investment plan for local production, their “under one roof” project for the Novartis entities, and the key strategies…
Joaquin Rodrigo, general director of Sandoz Spain and Portugal, introduces the company’s highly diversified generics and biosimilars portfolio in the region, gives his thoughts on Spain’s generics market, and outlines…
Tim de Gavre, country head of Sandoz UK, discusses the role of biosimilars in driving innovation, the threats and opportunities of Brexit to the biosimilars industry, and how Sandoz partners…
Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration…
Michel Robidoux, president and general manager of Sandoz Canada, charts the extremely successful journey for this Novartis division. He explains the strategy Sandoz Canada has undertaken to expand its portfolio…
Kuntal Baveja, country head and president of Sandoz Philippines Corporation discusses the company’s expanding portfolio in the country and how the booming generic industry over the past years has helped…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
Manlio Florenzano discusses Sandoz’s engagement in Italy and the role of generics firms in contributing to a more affordable and sustainable Italian healthcare system. Can you please start by introducing…
The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics. Could you please…
Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players……
Mr. Willis, you have a background as a management consultant in New Zealand and Australia. What was the situation of the generics market when you arrived in the Philippines and…
Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in…
Many companies that are focused in the diabetes segment have recognised the need to strengthen their operations in emerging markets, due to the increased prevalence of the disease in countries…
You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process…
The acquisition of Jerini has to be one of the biggest milestones for Shire Deutschland in its recent history. How have the synergies developed between the two companies, and how…
You arrived at Grünenthal fairly recently, in January of this year. What was it about the company that attracted you to the position? That goes back to 1987, when I…
Roche, once a true pharmaceutical company, is now recognized by its capacity to create a unique business model that allowed to become the world’s largest biotech company with truly differentiated…
Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The…
Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community.…
Why was the time right in 2000 to start Paion, and how did your background and experiences in the pharma industry, academia and consulting help you create the successful company…
One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the…
You have a wide professional experience that goes from financial adviser to biotechnology entrepreneur, passing through software business and politics. How will all of those different experiences enable you to…
Your interest in bioinformatics has run though your academic career and now into your business career as CEO and founder of Biomax Informatics; what was your vision for the company…
Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been…
See our Cookie Privacy Policy Here
